Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $16000.0.

  • Ovid Therapeutics' Depreciation & Amortization (CF) fell 9053.25% to $16000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $416000.0, marking a year-over-year decrease of 2984.82%. This contributed to the annual value of $613000.0 for FY2024, which is 792.25% up from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Depreciation & Amortization (CF) is $16000.0, which was down 9053.25% from $99000.0 recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $184980.0 for Q4 2022, and its period low was $16000.0 during Q3 2025.
  • In the last 5 years, Ovid Therapeutics' Depreciation & Amortization (CF) had a median value of $137000.0 in 2023 and averaged $115083.4.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 22480.55% in 2022, then plummeted by 9053.25% in 2025.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Depreciation & Amortization (CF) stood at $56951.0 in 2021, then soared by 224.81% to $184980.0 in 2022, then decreased by 24.32% to $140000.0 in 2023, then grew by 14.29% to $160000.0 in 2024, then crashed by 90.0% to $16000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $16000.0 in Q3 2025, compared to $99000.0 in Q2 2025 and $141000.0 in Q1 2025.